Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.

• Revenue in USD (TTM)0.00
• Net income in USD-73.53m
• Incorporated1987
• Employees15.00

• Location
  Seelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
• Phone+1 (646) 293-2100
• Fax+1 (858) 436-8155
• Websitehttps://seelostherapeutics.com/